GLOBAL IMMUNOGLOBULIN MARKET 2022-2028

Lifesciences | Diagnostic & Biotechnology

GLOBAL IMMUNOGLOBULIN MARKET 2022-2028

Market by Type, Delivery Mode, Application, End-user, Sales Channel, and Regional Outlook | Forecast 2022-2028

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

Immunoglobulins refer to the antibodies produced naturally by the body's immune system and help fight infections and diseases. These glycoprotein molecules generated by the plasma cells act as a critical component of the body's immune response by identifying and binding to specific antigens like viruses and bacteria while aiding in their destruction.

According to Triton Market Research's analysis, the Global Immunoglobulin Market was valued at $13616.82 million in 2021 and is expected to reach $21497.75 million by 2028, growing at a CAGR of 6.77% during the forecast period of 2022-2028.

Click here to check out our blog on the Global Immunoglobulin Market

MARKET PERFORMANCE – DRIVERS, CHALLENGES, AND TRENDS

During the forecast period, the market expansion will likely be fueled by growth in the geriatric population, the prevalence of immunodeficiency diseases and autoimmune disorders, and increasing research and development activities. The elderly population is at risk for increased immunodeficiency diseases and the severity of certain infections. Also, aging is related to abnormalities related to humoral immunity. In addition, with an increase in age, there is a rise in the prevalence of different infections and cancers. Also, it is being observed that autoimmune processes play a crucial role in developing a range of pathological conditions like atherosclerosis. As per WHO, 1 (in 6) people worldwide will be aged 60 years or more by 2030. Also, the population with age 60 years or older is projected to reach 1.4 billion by 2030 from 1 billion in 2020. Such factors result in market growth.

The market must overcome significant obstacles like the high cost of therapy and the high risk of side effects due to the use of immunoglobulin. The cost of human immunoglobulin therapies is directly related to the type of delivery method used and the site of care. According to the National Center for Biotechnology Information, the average cost per intravenous immunoglobulin infusion in the United States has been reported to be $ 9,720, and patients receive 4.3 infusions per month on average. Therefore, the total intravenous immunoglobulin costs would be $41,796 per month. The treatment may last up to a few months owing to which the complete therapy becomes a costly process.

The rising preference for personalized medicine is likely to have a positive impact on the growth of the global immunoglobulin market during the forecast period. Patients across the world are increasingly opting for personalized medicines owing to the wide range of benefits it offers. Personalized medicine possesses the potential to provide improved medication selection & targeted therapy, reduce adverse effects, increase patient compliance, enhance cost-effectiveness, shift the objective of medicine from reaction to prevention and also increase patient confidence. All these factors are expected to further boost developments in the use of immunoglobulins as personalized medicines.


Report scope can be customized per your requirements. Request For Customization         

KEY GEOGRAPHIES COVERED:

•         North America: United States and Canada

•         Europe: United Kingdom, France, Germany, Spain, Italy, and Rest of Europe

•         Asia-Pacific: China, Japan, India, South Korea, ASEAN Countries, Australia & New Zealand, and Rest of Asia-Pacific

•         Latin America: Brazil, Mexico, and Rest of Latin America

•         Middle East and Africa: United Arab Emirates, Saudi Arabia, Turkey, South Africa, and Rest of Middle East & Africa

 

SEGMENTATION ANALYSIS – IMMUNOGLOBULIN MARKET:

•         Market by Product:

o        IgG

o        IgA

o        IgM

o        IgE

o        IgD

Immunoglobulin G is expected to dominate the market during the forecast period. It is the most common antibody type found in blood circulation and represents approximately 75% of serum antibodies in the human body. Immunoglobulin G molecules are created and released by plasma B cells, and each immunoglobulin G antibody has two paratopes. It is the only class of immunoglobulin capable of crossing the placenta in humans and is largely responsible for the protection of the newborn during the first months of life. Immunoglobulin G is the principal antibody used in clinical diagnostics and immunological research owing to its excellent specificity toward antigens and relative abundance. Also, immunoglobulin G is the major immunoglobulin in lymph fluid, blood, peritoneal fluid, and cerebrospinal fluid and a key player in the humoral immune response. Serum immunoglobulin G in healthy humans presents about 15% of total protein besides enzymes, albumins, other globulins, and many more.

•         Market by Delivery Mode:

o        Intravenous

o        Subcutaneous

o        Intramuscular 

Intravenous is expected to dominate the market during the forecast periodIntravenous immunoglobulin is used for the reduction of the results of a few inflammatory conditions that involve the immune system (autoimmune diseases). It is also used to increase the immunoglobulin level if it is low or decreased by the treatment through other drugs, which includes rituximab.

•         Market by Application:

o        Hypogamma Globulinemia

o        Chronic Inflammatory demyelinating polyneuropathy

o        Primary Immunodeficiency diseases

o        Myasthenia Gravis

o        Multifocal motor neuropathy

o        Idiopathic thrombocytopenic purpura (ITP)

o        Inflammatory Myopathies

o        Specific antibody deficiency

o        Guillain-Barre syndrome

o        Other Applications

•         Market by End-user:

o        Hospitals & Clinics

o        Homecare

•         Market by Sales Channel:

o        Hospital pharmacy

o        Specialty pharmacy

o        Other Distribution Channels

 

 

COMPETITIVE LANDSCAPE:

The competitive landscape helps dive into data about the key players in the Immunoglobulin market. The strategic initiatives for each of the companies considered have been covered in detail.

 

Partnership (January 2022): LFB Group and Kedrion

In 2022, LFB Group and Kedrion announced a partnership to increase the availability of immunoglobulin (a plasma-derived medicine) for patients across France.

Agreement (March 2020): Grifols and Shanghai RAAS

In 2020, Grifols and Shanghai RAAS announced their strategic alliance to promote the growth of plasma-derived products and diagnostic solutions across China.

 

Key Benefits of the Report:

   Triton Market Research has a collective experience of 25-30 years in the industry, with its analysts and experts encompassing the most infallible research methodology for its market intelligence and industry analysis.

 

     Our research methodology helps in achieving a broader consensus of the market size, shape, and industry trends within each industry segment.

 

  The strategy adopted in designing the research methodology includes the amalgamation of the information assembled from primary and secondary sources, with the assistance of analytical tools to construct the forecast and predictive models.

 

    The scope of the market report comprises the current scenario of the global immunoglobulin market, along with the detailed overview of the industry outlook, market dynamics, segmentation analysis, regional outlook, and competitive landscape for the period 2022-2028.

 

 

FAQs:

Q 1) Does this report include the impact of covid-19 on the immunoglobulin market?

The market study has analyzed the impact of COVID-19 ON the immunoglobulin market qualitatively and quantitatively.

Q 2) Which product type is dominating?

Immunoglobulin G accounted for the largest market share in terms of revenue in 2021 and is expected to dominate the market during the forecast period.

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1. GLOBAL IMMUNOGLOBULIN MARKET – SUMMARY

2. INDUSTRY OUTLOOK

2.1. IMPACT OF COVID-19 ON THE IMMUNOGLOBULIN MARKET

2.2. KEY INSIGHTS

2.2.1. DEVELOPMENT OF NEW PURIFICATION METHODS

2.2.2. INCREASING PREFERENCE FOR PERSONALIZED MEDICINES

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1. THREAT OF NEW ENTRANTS

2.3.2. THREAT OF SUBSTITUTES

2.3.3. BARGAINING POWER OF BUYERS

2.3.4. BARGAINING POWER OF SUPPLIERS

2.3.5. THREAT OF COMPETITIVE RIVALRY

2.4. MARKET ATTRACTIVENESS INDEX

2.5. VENDOR SCORECARD

2.6. KEY MARKET STRATEGIES

2.6.1. PRODUCT LAUNCHES & DEVELOPMENTS

2.6.2. PARTNERSHIPS & AGREEMENTS

2.7. MARKET DRIVERS

2.7.1. GROWTH IN THE GERIATRIC POPULATION

2.7.2. PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS

2.7.3. INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

2.8. MARKET CHALLENGES

2.8.1. HIGH COST OF THERAPY

2.8.2. HIGH RISK OF SIDE EFFECTS DUE TO THE USE OF IMMUNOGLOBULIN

2.9. MARKET OPPORTUNITIES

2.9.1. INCREASING ADOPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENTS

2.9.2. GROWING CLINICAL TRIALS

3. GLOBAL IMMUNOGLOBULIN MARKET OUTLOOK – BY TYPE

3.1. IGG

3.2. IGA

3.3. IGM

3.4. IGE

3.5. IGD

4. GLOBAL IMMUNOGLOBULIN MARKET OUTLOOK – BY DELIVERY MODE

4.1. INTRAVENOUS

4.2. SUBCUTANEOUS

4.3. INTRAMUSCULAR

5. GLOBAL IMMUNOGLOBULIN MARKET OUTLOOK – BY APPLICATION

5.1. HYPOGAMMA GLOBULINEMIA

5.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

5.3. PRIMARY IMMUNODEFICIENCY DISEASES

5.4. MYASTHENIA GRAVIS

5.5. MULTIFOCAL MOTOR NEUROPATHY

5.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

5.7. INFLAMMATORY MYOPATHIES

5.8. SPECIFIC ANTIBODY DEFICIENCY

5.9. GUILLAIN-BARRE SYNDROME

5.10. OTHER APPLICATIONS

6. GLOBAL IMMUNOGLOBULIN MARKET OUTLOOK – BY END-USER

6.1. HOSPITALS & CLINICS

6.2. HOMECARE

7. GLOBAL IMMUNOGLOBULIN MARKET OUTLOOK – BY SALES CHANNEL

7.1. HOSPITAL PHARMACY

7.2. SPECIALTY PHARMACY

7.3. OTHER SALES CHANNELS

8. GLOBAL IMMUNOGLOBULIN MARKET – REGIONAL OUTLOOK

8.1. NORTH AMERICA

8.1.1. MARKET BY TYPE

8.1.2. MARKET BY DELIVERY MODE

8.1.3. MARKET BY APPLICATION

8.1.4. MARKET BY END-USER

8.1.5. MARKET BY SALES CHANNEL

8.1.6. COUNTRY ANALYSIS

8.1.6.1. UNITED STATES

8.1.6.2. CANADA

8.2. EUROPE

8.2.1. MARKET BY TYPE

8.2.2. MARKET BY DELIVERY MODE

8.2.3. MARKET BY APPLICATION

8.2.4. MARKET BY END-USER

8.2.5. MARKET BY SALES CHANNEL

8.2.6. COUNTRY ANALYSIS

8.2.6.1. UNITED KINGDOM

8.2.6.2. GERMANY

8.2.6.3. FRANCE

8.2.6.4. SPAIN

8.2.6.5. ITALY

8.2.6.6. REST OF EUROPE

8.3. ASIA-PACIFIC

8.3.1. MARKET BY TYPE

8.3.2. MARKET BY DELIVERY MODE

8.3.3. MARKET BY APPLICATION

8.3.4. MARKET BY END-USER

8.3.5. MARKET BY SALES CHANNEL

8.3.6. COUNTRY ANALYSIS

8.3.6.1. CHINA

8.3.6.2. JAPAN

8.3.6.3. INDIA

8.3.6.4. SOUTH KOREA

8.3.6.5. ASEAN COUNTRIES

8.3.6.6. AUSTRALIA & NEW ZEALAND

8.3.6.7. REST OF ASIA-PACIFIC

8.4. LATIN AMERICA

8.4.1. MARKET BY TYPE

8.4.2. MARKET BY DELIVERY MODE

8.4.3. MARKET BY APPLICATION

8.4.4. MARKET BY END-USER

8.4.5. MARKET BY SALES CHANNEL

8.4.6. COUNTRY ANALYSIS

8.4.6.1. BRAZIL

8.4.6.2. MEXICO

8.4.6.3. REST OF LATIN AMERICA

8.5. MIDDLE EAST AND AFRICA

8.5.1. MARKET BY TYPE

8.5.2. MARKET BY DELIVERY MODE

8.5.3. MARKET BY APPLICATION

8.5.4. MARKET BY END-USER

8.5.5. MARKET BY SALES CHANNEL

8.5.6. COUNTRY ANALYSIS

8.5.6.1. UNITED ARAB EMIRATES

8.5.6.2. SAUDI ARABIA

8.5.6.3. TURKEY

8.5.6.4. SOUTH AFRICA

8.5.6.5. REST OF MIDDLE EAST & AFRICA

9. COMPETITIVE LANDSCAPE

9.1. BIOTEST AG

9.2. CHINA BIOLOGIC PRODUCTS INC

9.3. GRIFOLS SA

9.4. LFB GROUP

9.5. CSL BEHRING

9.6. KEDRION BIOPHARMA

9.7. OCTAPHARMA AG

9.8. TAKEDA PHARMACEUTICAL COMPANY LIMITED

9.9. BIO PRODUCTS LABORATORY

9.10. SHANGHAI RAAS BLOOD PRODUCTS CO LTD

9.11. PFIZER INC

9.12. SANQUIN PLASMA PRODUCTS BV

9.13. ADMA BIOLOGICS

9.14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

9.15. KAMADA LTD

10. RESEARCH METHODOLOGY & SCOPE

10.1. RESEARCH SCOPE & DELIVERABLES

10.2. SOURCES OF DATA

10.3. RESEARCH METHODOLOGY

List of Tables

TABLE 1: GLOBAL IMMUNOGLOBULIN MARKET, BY REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 2: VENDOR SCORECARD

TABLE 3: GLOBAL IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 4: GLOBAL IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 5: GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 6: GLOBAL IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 7: GLOBAL IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

TABLE 8: GLOBAL IMMUNOGLOBULIN MARKET, BY REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 9:   NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 10: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 11: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 12: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 13: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 14: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

TABLE 15: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 16: EUROPE IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 17: EUROPE IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 18: EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 19: EUROPE IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 20: EUROPE IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

TABLE 21: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 22: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 23: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 24: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 25: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 26: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

TABLE 27: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 28: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 29: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 30: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 31: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 32: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

TABLE 33: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 34: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 35: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 36: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 37: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 38: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

List of Figures

FIGURE 1: MARKET ATTRACTIVENESS INDEX

FIGURE 2: GLOBAL IMMUNOGLOBULIN MARKET, BY TYPE, 2021 & 2028 (IN %)

FIGURE 3: GLOBAL IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)

FIGURE 4: GLOBAL IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)

FIGURE 5: GLOBAL IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)

FIGURE 6: GLOBAL IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)

FIGURE 7: GLOBAL IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)

FIGURE 8: GLOBAL IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2021 & 2028 (IN %)

FIGURE 9: GLOBAL IMMUNOGLOBULIN MARKET, BY INTRAVENOUS, 2022-2028 (IN $ MILLION)

FIGURE 10: GLOBAL IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS, 2022-2028 (IN $ MILLION)

FIGURE 11: GLOBAL IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR, 2022-2028 (IN $ MILLION)

FIGURE 12: GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 2021 & 2028 (IN %)

FIGURE 13: GLOBAL IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $ MILLION)

FIGURE 14: GLOBAL IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 15: GLOBAL IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028 (IN $ MILLION)

FIGURE 16: GLOBAL IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)

FIGURE 17: GLOBAL IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 18: GLOBAL IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2028 (IN $ MILLION)

FIGURE 19: GLOBAL IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $ MILLION)

FIGURE 20: GLOBAL IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $ MILLION)

FIGURE 21: GLOBAL IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $ MILLION)

FIGURE 22: GLOBAL IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)

FIGURE 23: GLOBAL IMMUNOGLOBULIN MARKET, BY END-USER, 2021 & 2028 (IN %)

FIGURE 24: GLOBAL IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)

FIGURE 25: GLOBAL IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)

FIGURE 26: GLOBAL IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2021 & 2028 (IN %)

FIGURE 27: GLOBAL IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 28: GLOBAL IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 29: GLOBAL IMMUNOGLOBULIN MARKET, BY OTHER SALES CHANNELS, 2022-2028 (IN $ MILLION)

FIGURE 30: GLOBAL IMMUNOGLOBULIN MARKET, REGIONAL OUTLOOK, 2021 & 2028 (IN %)

FIGURE 31: UNITED STATES IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 32: CANADA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 33: UNITED KINGDOM IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 34: GERMANY IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 35: FRANCE IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 36: SPAIN IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 37: ITALY IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 38: REST OF EUROPE IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 39: CHINA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 40: JAPAN IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 41: INDIA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 42: SOUTH KOREA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 43: ASEAN COUNTRIES IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 44: AUSTRALIA & NEW ZEALAND IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 45: REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 46: BRAZIL IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 47: MEXICO IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 48: REST OF LATIN AMERICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 49: UNITED ARAB EMIRATES IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 50: SAUDI ARABIA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 51: TURKEY IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 52: SOUTH AFRICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 53: REST OF MIDDLE EAST & AFRICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$2,750.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$4,000.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;